A Better Tomorrow with HanAll

Innovative Therapeutics to Address Unmet Medical Needs of Patients

Developing Innovations for Healthier,
Longer lives for Patients

Committed to Pioneering Next
Generation Technology

Our company pledges to make meaningful contributions to patients by
improving current medical practices. We believe in science, take risks for
innovations, learn from mistakes, and humbly serve the patients.
HanAll is primed to develop innovative,
impactful therapies to address unmet medical needs
A novel, topical, anti-TNF alpha protein drug for the treatment
of inflammatory eye diseases including dry eye disease
A novel, anti-FcRn antibody for the treatment
of autoimmune diseases
Next-generation immune checkpoint inhibitor